Cover Image
市場調查報告書

OpportunityAnalyzer:胰臟癌 - 機會分析與預測

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

出版商 GlobalData 商品編碼 298492
出版日期 內容資訊 英文 179 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:胰臟癌 - 機會分析與預測 OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
出版日期: 2014年03月27日 內容資訊: 英文 179 Pages
簡介

主要6個國家(美國、法國、德國、義大利、西班牙、英國)的胰臟癌治療藥市場預測將從2012年的5億2,900萬美金擴大到2017年16億3,000萬美金,達到CAGR25.2%的急速成長。臨床診療採用了高價的Abraxane,以及有五種新管道藥的預定發售,是這個成長的背景。

本報告提供胰臟癌的治療藥市場相關調查分析,提供疾病概要,流行病學,目前治療選項,未滿足需求分析,機會分析,研究開發策略,開發平台評估等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 預測
  • 臨床階段
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 風險因素和併發症
    • 胰臟癌的發病風險隨著高齡化而增加
    • 吸煙者的胰臟癌發病風險為2倍
    • 糖尿病和肥胖會增加胰臟癌的發病風險
    • 至少10%的胰臟癌患者原因為遺傳
  • 全球趨勢
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
    • 發病數量
    • 5年的患病數量
  • 議論
    • 流行病學趨勢的考察
    • 分析的限制
    • 分析的優勢

第5章 目前治療選項

  • 概要
  • 產品簡介:領導品牌

第6章 未滿足需求與評估機會分析

  • 概要
  • 未滿足需求分析
  • 機會分析

第7章 研究開發(R&D)策略

  • 概要
  • 臨床試驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發中的有前途藥物
  • 初期階段的創新的方法

第9章 開發平台評估分析

  • 主要開發平台藥物臨床基準
  • 主要開發平台藥物的商業基準
  • 競爭評估
  • 銷售額的5年預測
    • 美國
    • 歐洲

第10章 附錄

圖表

目錄
Product Code: GDHC016POA

With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the pancreatic cancer market with coverage of both the early stage resectable and advanced settings. Celgene's Abraxane was launched in the US and Europe in 2013 and 2014, respectively, and was the first drug approved in this disease in nearly a decade. Due to the high unmet need, GlobalData forecasts the rapid uptake of Abraxane, and sales of this drug are expected to drive the overall pancreatic cancer market and are forecast to represent greater than 50% of total market sales in 2017. GlobalData also forecasts the launch of five new pipeline agents into the pancreatic cancer market. Despite the launch of new agents, GlobalData expects significant opportunities to remain for developers of drugs with predictive biomarker-driven strategies. The challenge for new entrants will be to design adequate clinical studies that assess pipeline drugs in carefully selected patient populations and incorporate the current standard-of-care chemotherapies, such as GemAbrax, as backbone regimens. With Big Pharma being actively involved in early-stage innovative projects, GlobalData expects clinical development in pancreatic cancer to accelerate at the end of the forecast period and beyond.

Highlights

Key Questions Answered

  • What are the areas of highest unmet need in pancreatic cancer?
  • What are the R&D and clinical trial design strategies pursued by companies in the pancreatic cancer space?
  • What are the most promising pipeline agents for pancreatic cancer? How do their clinical and commercial attributes compare to one another and the current standard of care?
  • What opportunities will remain for future players following the launch of these pipeline agents?
  • What is the potential for predictive biomarkers and targeted therapies in the pancreatic cancer setting?
  • What exciting, innovative approaches are being investigated in pancreatic cancer?

Key Findings

  • The pancreatic cancer market, in the 6MM is forecasted to rapidly increase from $529m in 2012 to $1.63bn in 2017, at a CAGR of 25.2%. This growth is driven by the adoption of premium-priced Abraxane into clinical practice, as well as the launch of five novel pipeline agents towards the end of the forecast period.
  • Although the approval of Abraxane has been welcomed by KOLs, they are not satisfied with the overall survival benefit of two months compared with gemcitabine monotherapy, and call for novel, predictive, biomarker-driven targeted therapies in order to substantially extend survival.
  • Of the pipeline agents expected to launch during the forecast period, only NewLink Genetics' immunotherapy algenpantucel-L is being investigated in the early-stage resectable setting. GlobalData expects the lack of treatment options for resectable patients to facilitate the rapid uptake of this therapy in the US.
  • The early stage pipeline for pancreatic cancer is strong and is indicative of the remaining high commercial opportunities. Strikingly, in comparison with the late-stage pipeline, Big Pharma is playing a much stronger role in the investigation of these strategies.

Scope

  • Overview of pancreatic cancer, including epidemiology, etiology, pathophysiology, symptoms, prognosis, and clinical staging.
  • Topline pancreatic cancer therapeutics market revenue from 2012-2017. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the pancreatic cancer therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the 6MM pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 6MM pancreatic cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 6MM pancreatic cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Prognosis
  • 3.3. Clinical Staging
  • 3.4. Symptoms

4. Epidemiology

  • 4.1. Disease Overview
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. The risk of developing pancreatic cancer increases with age
    • 4.2.2. Tobacco smokers have a two-fold increased risk of pancreatic cancer
    • 4.2.3. Diabetes and obesity increase the risk of developing pancreatic cancer
    • 4.2.4. At least 10% of pancreatic cancer cases result from a hereditary predisposition
  • 4.3. Global Trends
    • 4.3.1. United States
    • 4.3.2. France
    • 4.3.3. Germany
    • 4.3.4. Italy
    • 4.3.5. Spain
    • 4.3.6. United Kingdom
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiology Forecast
    • 4.5.1. Incident Cases of Pancreatic Cancer
    • 4.5.2. Total Five-Year Prevalent Cases of Pancreatic Cancer
  • 4.6. Discussion
    • 4.6.1. Conclusions on Epidemiological Trends
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Abraxane
    • 5.2.2. Gemcitabine
    • 5.2.3. Tarceva

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Unmet Needs Analysis
    • 6.2.1. Therapies That Improve Overall Survival Outcomes for Advanced Patients
    • 6.2.2. Effective Adjuvant Treatments That Prevent Recurrence of Disease
    • 6.2.3. Earlier Diagnosis of Disease
    • 6.2.4. Discovery of Predictive Biomarkers and Understanding of Underlying Causes of Disease
    • 6.2.5. Treatment Options for Gemcitabine-Refractory Metastatic Patients
  • 6.3. Opportunity Analysis
    • 6.3.1. Predictive Biomarker-Driven Targeted Therapies in Combination with Chemotherapy Regimens
    • 6.3.2. Treatment for Patients with Early-Stage, Localized Pancreatic Cancer
    • 6.3.3. Target Patients with Poor Performance Status
    • 6.3.4. Effective Drug Delivery
    • 6.3.5. Establish New Chemotherapy to be Standard-of-Care Cytotoxic
    • 6.3.6. Development of New Standard of Care for Gemcitabine-Refractory Advanced Patients

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Reformulation strategies
    • 7.1.2. Small/Medium-Sized Pharmaceutical Companies Driving R&D
    • 7.1.3. Large Pharmaceutical Companies Betting On Targeted Drug Approaches
  • 7.2. Clinical Trial Design
    • 7.2.1. Overview
    • 7.2.2. Overall Survival is the Primary Endpoint of Choice in Both Adjuvant and Metastatic Trials
    • 7.2.3. The Majority of Metastatic Trials Are in Second-Line and Later Patients
    • 7.2.4. Gemcitabine: Backbone Therapy and Standard Active Comparator for First-Line Metastatic Trials

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Algenpantucel-L
    • 8.2.2. TH-302
    • 8.2.3. Lipoplatin
    • 8.2.4. MM-398
    • 8.2.5. Glufosfamide
    • 8.2.6. 90Y-Clivatuzumab Tetraxetan
  • 8.3. Innovative Early-Stage Approaches
    • 8.3.1. Vaccine and Immunotherapy Combination
    • 8.3.2. JAK Inhibition
    • 8.3.3. Dual MEK/PI3K inhibition
    • 8.3.4. Cancer Stem Cell Targeting
    • 8.3.5. Poly (ADP-Ribose) Polymerase Inhibitors
    • 8.3.6. Drug Delivery Mechanisms
    • 8.3.7. Hedgehog Pathway

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmarking of Key Pipeline Drugs
  • 9.2. Commercial Benchmarking of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
  • 9.5. US
  • 9.6. Europe

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Pancreatic Cancer Patients
    • 10.4.2. Percent Drug-Treated
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Authors
    • 10.6.2. Epidemiologists
    • 10.6.3. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: AJCC TNM Classification System for Pancreatic Cancer
  • Table 2: AJCC TNM Staging System for Pancreatic Cancer
  • Table 3: Common Pancreatic Cancer Symptoms
  • Table 4: Risk Factors for Pancreatic Cancer
  • Table 5: 6MM, Sources of Pancreatic Cancer Incidence Data
  • Table 6: 6MM, Incident Cases of Pancreatic Cancer, Ages ≥15 Years, Men and Women, Select Years, 2012-2022
  • Table 7: 6MM, Incident Cases of Pancreatic Cancer, by Age, Men and Women, N, 2012
  • Table 8: 6MM, Incident Cases of Pancreatic Cancer, by Sex, Ages ≥15 Years, N (Row %), 2012
  • Table 9: 6MM, Five-Year Prevalent Cases of Pancreatic Cancer, Ages ≥15 Years, Men and Women, Select Years, 2012-2022
  • Table 10: Leading Treatments for Pancreatic Cancer in the US and 5EU
  • Table 11: Product Profile - Abraxane
  • Table 12: Abraxane SWOT Analysis
  • Table 13: Gemcitabine SWOT Analysis
  • Table 14: Product Profile - Tarceva
  • Table 15: Tarceva SWOT Analysis
  • Table 16: Overall Unmet Needs - Current Level of Attainment
  • Table 17: Design of Pipeline Phase III Trials in Pancreatic Cancer
  • Table 18: Pancreatic Cancer - Late Stage Pipeline
  • Table 19: Product Profile - Algenpantucel-L
  • Table 20: Algenpantucel-L SWOT Analysis
  • Table 21: Product Profile - TH-302
  • Table 22: TH-302 SWOT Analysis
  • Table 23: Product Profile - Lipoplatin
  • Table 24: Lipoplatin SWOT Analysis
  • Table 25: Product Profile - MM-398
  • Table 26: MM-398 SWOT Analysis
  • Table 27: Product Profile - Glufosfamide
  • Table 28: Glufosfamide SWOT Analysis
  • Table 29: Product Profile - 90Y-Clivatuzumab Tetraxetan
  • Table 30: 90Y-Clivatuzumab Tetraxetan SWOT Analysis
  • Table 31: Early-Stage Pipeline Products in Pancreatic Cancer
  • Table 32: Clinical Benchmarking of Key Pipeline Drugs - Pancreatic Cancer
  • Table 33: Commercial Benchmarking of Key Pipeline Drugs - Pancreatic Cancer
  • Table 34: Top-Line Sales Forecast ($m) for Pancreatic Cancer, 2012-2017
  • Table 35: Key Events Impacting Sales for Pancreatic Cancer, 2012-2017
  • Table 36: Pancreatic Cancer Market - Drivers and Barriers, 2013
  • Table 37: Key Launch Dates 2012-2017
  • Table 38: Key Patent Expiries 2012-2017

List of Figures

  • Figure 1: Pancreatic Cancer Staging According to the AJCC TNM System
  • Figure 2: US, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008
  • Figure 3: France, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008
  • Figure 4: Germany, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008
  • Figure 5: Italy, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008
  • Figure 6: Spain, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008
  • Figure 7: UK, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008
  • Figure 8: 6MM, Incident Cases of Pancreatic Cancer, Ages ≥15 Years, Men and Women, Select Years, 2012-2022
  • Figure 9: 6MM, Incident Cases of Pancreatic Cancer, by Age, Men and Women, N, 2012
  • Figure 10: 6MM, Incident Cases of Pancreatic Cancer by Sex, Ages ≥15 Years, 2012
  • Figure 11: 6MM, Age-Standardized Pancreatic Cancer Incidence, 2012
  • Figure 12: 6MM, Incident Cases of Pancreatic Cancer by Stage at Diagnosis, Ages ≥15 Years, Men and Women, 2012
  • Figure 13: 6MM, Total Incident Biomarker Cases of Pancreatic Cancer, Ages ≥15 Years, Men and Women, 2012
  • Figure 14: 6MM, Total Five-Year Prevalent Cases of Pancreatic Cancer, Ages ≥15 Years, Men and Women, Select Years, 2012-2022
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in Pancreatic Cancer, 2012-2017
  • Figure 16: Global Sales for Pancreatic Cancer by Region, 2012-2017
Back to Top